

James Yun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4062978/publications.pdf>

Version: 2024-02-01

29
papers

839
citations

858243

12
h-index

563245

28
g-index

32
all docs

32
docs citations

32
times ranked

940
citing authors

#	ARTICLE	IF	CITATIONS
1	Reducing severe cutaneous adverse and type B adverse drug reactions using pre-€stored human leukocyte antigen genotypes. <i>Clinical and Translational Allergy</i> , 2022, 12, e12098.	1.4	4
2	Severe Delayed-Onset Neutropenia Induced by Ocrelizumab. <i>Neurohospitalist, The</i> , 2021, 11, 59-61.	0.3	10
3	A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 929-936.e7.	2.0	18
4	The role of intravenous immunoglobulin in treatment of refractory Felty syndrome c. <i>Internal Medicine Journal</i> , 2021, 51, 303-304.	0.5	1
5	Reintroduction of Antituberculous Drugs in Patients with Antituberculous Drug-Related Drug Reaction with Eosinophilia and Systemic Symptoms. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3442-3449.e3.	2.0	11
6	Disseminated sarcoidosis involving lymph nodes, bone and spleen with progressive cardiac sarcoidosis on 18F-FDG PET/CT and cardiac MRI. <i>Radiology Case Reports</i> , 2021, 16, 3610-3613.	0.2	0
7	A One-Bag Rapid Desensitization Protocol for Paclitaxel Hypersensitivity: A Noninferior Alternative to a Multi-Bag Rapid Desensitization Protocol. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 696-703.	2.0	24
8	Multicenter Australian Study to Determine Criteria for Low- and High-Risk Penicillin Testing in Outpatients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 681-689.e3.	2.0	39
9	Outcomes of Cancer Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: CardioOncology</i> , 2020, 2, 506-508.	1.7	4
10	HLA-DRB1*15. <i>Investigative Radiology</i> , 2020, 55, 304-309.	3.5	11
11	Behçet disease-€associated rhabdomyolysis treated with infliximab. <i>Internal Medicine Journal</i> , 2020, 50, 642-643.	0.5	1
12	Severe infusion reaction due to nivolumab: A case report. <i>Cancer Reports</i> , 2020, 3, e1246.	0.6	8
13	Development and Validation of a Penicillin Allergy Clinical Decision Rule. <i>JAMA Internal Medicine</i> , 2020, 180, 745.	2.6	135
14	Drug hypersensitivity reactions in Asia: regional issues and challenges. <i>Asia Pacific Allergy</i> , 2020, 10, e8.	0.6	15
15	Diagnostic procedures & practices in drug allergy/hypersensitivity: a survey of 13 Asian countries. <i>Asia Pacific Allergy</i> , 2020, 10, e36.	0.6	8
16	Immune checkpoint inhibitor-€mediated myocarditis and ventricular tachycardia storm. <i>HeartRhythm Case Reports</i> , 2019, 5, 497-500.	0.2	12
17	Carbonic anhydrase inhibitor-€induced Stevens-Johnson syndrome/toxic epidermal necrolysis leads to extensive cutaneous involvement. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2851-2853.e2.	2.0	6
18	Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2739-2749.e3.	2.0	17

#	ARTICLE	IF	CITATIONS
19	The Presence of HLA-B*75, DR13 Homozygosity, or DR14 Additionally Increases the Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in HLA-B*58:01 Carriers. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1261-1270.	2.0	15
20	Dapsone-induced drug reaction with eosinophilia and systemic symptoms associated with HLA-B*13:01. <i>Internal Medicine Journal</i> , 2018, 48, 363-364.	0.5	10
21	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome successfully treated with mepolizumab. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1059-1060.	2.0	29
22	Anaphylaxis to diphenylcyclopropanone during sensitization for wart treatment—A case report. <i>JAAD Case Reports</i> , 2018, 4, 872-873.	0.4	5
23	Skeletal myositis as the sole feature of relapsing drug reaction with eosinophilia and systemic symptoms syndrome. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 726-728.	0.5	4
24	Multiple Drug Hypersensitivity. <i>International Archives of Allergy and Immunology</i> , 2017, 172, 129-138.	0.9	67
25	T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevance. <i>Asia Pacific Allergy</i> , 2016, 6, 77-89.	0.6	38
26	Allopurinol hypersensitivity: investigating the cause and minimizing the risk. <i>Nature Reviews Rheumatology</i> , 2016, 12, 235-242.	3.5	139
27	Drug Hypersensitivity: How Drugs Stimulate T Cells via Pharmacological Interaction with Immune Receptors. <i>International Archives of Allergy and Immunology</i> , 2015, 168, 13-24.	0.9	71
28	Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01. <i>Journal of Immunology</i> , 2014, 192, 2984-2993.	0.4	136
29	<i>Allergies</i> , 2014, , 323-328.		0